Plerixafor Seacross (Plerixafor)
CXCR4 Antagonist for Haematopoietic Stem Cell Mobilisation
Quick Facts About Plerixafor Seacross
Key Takeaways About Plerixafor Seacross
- Generic formulation: Plerixafor Seacross contains the same active ingredient (plerixafor 20 mg/ml) as the originator product Mozobil and is therapeutically equivalent for stem cell mobilisation
- Used alongside G-CSF: Always administered in combination with G-CSF to maximise mobilisation of stem cells from the bone marrow into the bloodstream for collection by apheresis
- For poor mobilisers: Primarily indicated for patients with lymphoma or multiple myeloma who cannot mobilise sufficient stem cells with G-CSF alone for autologous transplantation
- Rapid onset of action: Stem cell mobilisation begins within hours of the subcutaneous injection, with peak CD34+ cell counts occurring 9–14 hours after dosing
- Short hospital-based treatment: Given by healthcare professionals as a subcutaneous injection 6–11 hours before each apheresis session, typically for 2–4 consecutive days (maximum 7 days)
What Is Plerixafor Seacross and What Is It Used For?
Plerixafor Seacross is a generic formulation of plerixafor, a CXCR4 chemokine receptor antagonist that mobilises haematopoietic stem cells from the bone marrow into the peripheral blood. It is used in combination with G-CSF to facilitate stem cell collection (apheresis) before autologous stem cell transplantation in patients with lymphoma, multiple myeloma, or certain paediatric cancers.
Haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for various haematological malignancies, including non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma. The procedure involves collecting the patient's own stem cells (autologous transplant), administering high-dose chemotherapy to destroy cancerous cells, and then reinfusing the collected stem cells to reconstitute the bone marrow and restore normal blood cell production. A critical step in this process is mobilisation – the process of moving enough stem cells from the bone marrow into the peripheral blood so that they can be collected efficiently.
Traditionally, G-CSF (granulocyte colony-stimulating factor, also known as filgrastim or lenograstim) has been the primary agent used for stem cell mobilisation. G-CSF stimulates the bone marrow to produce more white blood cells and stem cells, gradually releasing them into the bloodstream over several days. However, a significant proportion of patients – estimated at 15–40% depending on the underlying disease, prior therapy, and age – fail to mobilise adequate numbers of CD34+ stem cells with G-CSF alone. These patients are termed "poor mobilisers" and may face delays in transplantation or require multiple apheresis sessions to reach the required cell dose.
Plerixafor Seacross addresses this challenge through a distinct and complementary mechanism of action. Plerixafor, the active substance, is a selective, reversible antagonist of the CXCR4 chemokine receptor. Under normal physiological conditions, the chemokine stromal cell-derived factor-1 alpha (SDF-1α, also known as CXCL12) binds to the CXCR4 receptor on the surface of haematopoietic stem cells, effectively anchoring them within the bone marrow microenvironment. By blocking this CXCR4/SDF-1α interaction, plerixafor releases stem cells from their bone marrow niche, causing a rapid and significant increase in circulating CD34+ cells within hours of injection.
When used together, G-CSF and plerixafor act synergistically: G-CSF expands the stem cell pool and initiates gradual mobilisation over 4–5 days, while plerixafor provides an additional acute mobilisation boost. Pivotal randomised controlled trials have demonstrated that the combination of G-CSF plus plerixafor results in significantly higher CD34+ cell yields and a greater proportion of patients reaching the target cell dose for transplantation compared with G-CSF alone.
Approved Indications
Plerixafor Seacross is approved for the following indications, always in combination with G-CSF:
- Adults with lymphoma or multiple myeloma: To enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients who are poor mobilisers
- Children aged 1 year to under 18 years: With lymphoma or solid tumours, to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation when cells are insufficient with G-CSF alone
Plerixafor Seacross is one of several generic plerixafor products approved after the originator (Mozobil, Sanofi Genzyme) lost its primary patent protection. Generic plerixafor formulations contain the same active substance at the same concentration (20 mg/ml) and are required by regulators such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) to demonstrate the same quality, safety, and efficacy as the originator product. This allows wider patient access and reduces healthcare costs without compromising clinical outcomes.
What Should You Know Before Using Plerixafor Seacross?
Before receiving Plerixafor Seacross, inform your doctor about all medical conditions, especially heart problems, kidney disease, high white blood cell counts, low platelet counts, or a history of leukaemia. Plerixafor Seacross should not be used in patients with leukaemia or known hypersensitivity to plerixafor.
Contraindications
You should not receive Plerixafor Seacross if any of the following apply:
- Hypersensitivity to plerixafor or any of the excipients (sodium chloride, hydrochloric acid, sodium hydroxide, or water for injections) – allergic reactions including anaphylaxis have been reported
- Leukaemia (cancer of the blood or bone marrow): Plerixafor should not be used for stem cell mobilisation in patients with leukaemia due to the theoretical risk of mobilising leukaemic cells into the peripheral blood, which could potentially contaminate the autologous graft
Warnings and Precautions
Talk to your doctor or haematologist before receiving Plerixafor Seacross if you have or have had any of the following conditions:
- Cardiovascular problems: Patients with cardiac risk factors should be monitored closely. In clinical studies, myocardial infarction (heart attack) has been reported uncommonly in patients receiving plerixafor in combination with G-CSF who had pre-existing cardiac risk factors. Inform your doctor immediately if you experience chest pain, shortness of breath, or any cardiac symptoms during treatment
- Kidney problems: Plerixafor is primarily excreted by the kidneys. If you have moderate to severe renal impairment (creatinine clearance ≤50 ml/min), your doctor will reduce the dose by one-third. There is limited clinical experience in patients with severe renal impairment or those on dialysis
- High white blood cell count (leukocytosis): Both G-CSF and plerixafor cause an increase in circulating white blood cells. Your doctor will monitor your blood counts regularly throughout treatment. If your white blood cell count exceeds 100 × 109/L, your doctor may consider discontinuing Plerixafor Seacross
- Low platelet count (thrombocytopenia): Thrombocytopenia has been associated with apheresis and with the use of plerixafor. Platelet counts should be monitored in all patients receiving Plerixafor Seacross, particularly in those undergoing repeated apheresis sessions
- Spleen enlargement: G-CSF alone and in combination with plerixafor has been associated with splenic enlargement, and rare cases of splenic rupture have been reported. Inform your doctor immediately if you experience pain in the upper left abdomen or left shoulder tip, as these may be signs of splenic problems
- History of fainting or vasovagal reactions: If you have previously felt faint, dizzy, or have fainted during or after injections, inform your healthcare team so appropriate precautions can be taken
Rash, swelling around the eyes, shortness of breath or difficulty breathing, lightheadedness when standing or sitting, or feeling faint or actually fainting shortly after receiving Plerixafor Seacross. These may be signs of a serious allergic reaction (anaphylaxis). Also seek urgent medical attention for pain in the upper left abdomen or left shoulder, which may indicate splenic enlargement or rupture.
Pregnancy and Breastfeeding
Plerixafor Seacross should not be used during pregnancy. There is no clinical experience with plerixafor in pregnant women, and animal reproductive studies have demonstrated adverse effects on the developing foetus, including teratogenicity and embryotoxicity. Women of childbearing potential must use effective contraception during treatment with Plerixafor Seacross.
Breastfeeding should be discontinued during treatment with Plerixafor Seacross. It is not known whether plerixafor or its metabolites are excreted in human breast milk. Given the potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the importance of the therapy to the mother.
Regarding fertility, the effects of plerixafor on male and female fertility in humans are unknown. Animal studies have not shown significant effects on fertility at clinically relevant doses, but patients and their partners should discuss any concerns with the treating specialist before starting treatment.
Driving and Operating Machinery
Plerixafor Seacross can cause dizziness and fatigue. Patients who experience these symptoms should avoid driving vehicles or operating machinery. Given that Plerixafor Seacross is administered in a hospital or clinical setting as part of a stem cell mobilisation programme, patients are typically under medical supervision and are unlikely to need to drive immediately after receiving the injection. It is advisable to arrange transport to and from the hospital during the mobilisation period.
Sodium Content
This medicine contains less than 1 mmol sodium (23 mg) per dose, which means it is essentially sodium-free. This information is relevant for patients on a controlled sodium diet, although the amounts involved are clinically negligible.
How Does Plerixafor Seacross Interact with Other Drugs?
Plerixafor Seacross has relatively few known drug interactions because plerixafor is not metabolised by cytochrome P450 enzymes. However, it is always used in combination with G-CSF, and the interaction between these two drugs is central to its therapeutic effect. Tell your doctor about all medicines you are currently taking, including non-prescription and herbal products.
Plerixafor is not significantly metabolised by hepatic cytochrome P450 enzymes (CYP450 system) and is primarily excreted unchanged by the kidneys. This pharmacokinetic profile means that clinically significant drug–drug interactions mediated through hepatic enzyme inhibition or induction are unlikely. In vitro studies indicate that plerixafor is neither a substrate nor an inhibitor of CYP450 enzymes and is not a substrate for P-glycoprotein.
Because plerixafor is eliminated primarily via renal excretion, drugs that significantly affect kidney function could potentially alter plerixafor clearance. Concurrent use of nephrotoxic agents should be approached with caution, and renal function should be monitored. Additionally, since both G-CSF and plerixafor increase white blood cell counts, the combination leads to significant leukocytosis, which must be monitored routinely throughout the mobilisation period.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| G-CSF (Filgrastim, Lenograstim, Pegfilgrastim) | Colony-stimulating factor | Synergistic enhancement of stem cell mobilisation; additive leukocytosis | Required combination – this is the intended clinical use. Monitor WBC counts regularly |
| Nephrotoxic agents (aminoglycosides, ciclosporin, amphotericin B) | Antibiotics / immunosuppressants | May reduce renal clearance of plerixafor, increasing drug exposure | Monitor renal function; dose adjustment of plerixafor may be needed |
| High-dose chemotherapy agents | Antineoplastic drugs | Chemo-mobilisation regimens may be used alongside G-CSF and plerixafor | Timing must be carefully coordinated by the transplant team |
Minor Interactions and Considerations
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Heparin and other anticoagulants | Anticoagulant | Used during apheresis procedures; combined with plerixafor-induced thrombocytopenia risk | Monitor platelet counts closely during apheresis sessions |
| Drugs that compete for renal tubular secretion | Various | Theoretical interaction due to shared elimination route | Not observed clinically; standard monitoring sufficient |
| NSAIDs (ibuprofen, naproxen) | Anti-inflammatory | May worsen renal function in susceptible patients | Avoid during mobilisation period if renal function is borderline |
| Live vaccines | Vaccines | Immunocompromised patients should avoid live vaccines | Not a direct plerixafor interaction but relevant in this patient population |
No formal drug interaction studies have been conducted with plerixafor beyond its mandatory combination with G-CSF. The primary route of elimination is renal, with approximately 70% of the dose excreted unchanged in urine within 24 hours. Therefore, drugs that compete for renal tubular secretion could theoretically interact with plerixafor, though this has not been observed clinically. Always consult the current Summary of Product Characteristics for the most up-to-date interaction information.
What Is the Correct Dosage of Plerixafor Seacross?
The recommended dose of Plerixafor Seacross for adults is either a fixed dose of 20 mg or a weight-based dose of 0.24 mg/kg body weight per day, given as a subcutaneous injection 6–11 hours before apheresis. The dose is reduced in patients with renal impairment. Treatment typically lasts 2–4 consecutive days.
Plerixafor Seacross is always used as part of a mobilisation regimen in combination with G-CSF. The G-CSF treatment is started first, typically 4–5 days before the first dose of plerixafor, to begin expanding and mobilising the stem cell population. Plerixafor Seacross is then added to provide an additional rapid mobilisation boost before each apheresis session.
Adults
Standard Adult Dosage
Dose: 20 mg (fixed dose) or 0.24 mg/kg body weight per day
Route: Subcutaneous injection
Timing: 6 to 11 hours before the start of each apheresis session
Duration: 2–4 consecutive days (up to a maximum of 7 days)
Notes: The patient's body weight should be measured within one week before the first dose. Treatment continues until sufficient stem cells have been collected for transplantation. The fixed 20 mg dose is recommended when body weight is up to 83 kg.
Renal Impairment (CrCl ≤50 ml/min)
Dose: Reduced to 0.16 mg/kg body weight per day (one-third reduction)
Route: Subcutaneous injection
Notes: The dose should not exceed 27 mg/day regardless of body weight. Limited data are available for patients with severe renal impairment (CrCl <20 ml/min) or those on haemodialysis. Close monitoring of serum creatinine and electrolytes is recommended throughout treatment.
Children (1 Year to Under 18 Years)
Paediatric Dosage
Dose: 0.24 mg/kg body weight per day
Route: Subcutaneous injection
Timing: 6 to 11 hours before apheresis
Duration: 2–4 consecutive days (up to 7 days)
Notes: Safety and efficacy have not been established in children below 1 year of age. Paediatric dosing is weight-based and should be determined by the treating specialist. The pivotal paediatric trial (DFI12860) supported the same weight-based dose across age groups from 1 to under 18 years.
Elderly Patients
No specific dose adjustment is recommended for elderly patients based solely on age. However, renal function declines with age, and dose adjustments should be made according to creatinine clearance using the same criteria as in younger adults. Elderly patients are also more likely to have pre-existing cardiac conditions, and cardiovascular monitoring is particularly important in this population throughout the mobilisation period.
How Is Plerixafor Seacross Given?
Plerixafor Seacross is administered by a healthcare professional (doctor or nurse) as a subcutaneous injection (injected under the skin). The injection is typically given in the upper arm, abdomen, or thigh. The following steps outline the usual mobilisation process:
- Days 1–4 (approximately): G-CSF is started at the standard mobilisation dose (typically 10 µg/kg/day) to begin stem cell expansion and initial mobilisation
- Evening of Day 4 (approximately): Plerixafor Seacross is given as a subcutaneous injection, 6–11 hours before the planned apheresis session on Day 5
- Day 5 morning: Apheresis is performed to collect stem cells from the peripheral blood
- Repeat: Steps 2–3 are repeated daily until sufficient stem cells have been collected (target is typically ≥2 × 106 CD34+ cells/kg for a single transplant, or ≥5 × 106 CD34+ cells/kg for optimal outcomes)
Missed Dose
Because Plerixafor Seacross is administered in a hospital or clinical setting under medical supervision, missed doses are uncommon. Should a dose be delayed or missed, the transplant team will reassess the mobilisation timeline and determine whether to proceed with apheresis, postpone collection, or administer the dose at an adjusted time. Do not attempt to adjust the timing yourself – always follow the instructions of the medical team.
Overdose
There is limited clinical experience with overdose of plerixafor. In a dose-escalation study in healthy volunteers, doses up to 0.48 mg/kg were investigated. The dose-limiting adverse effects at higher doses included gastrointestinal symptoms (nausea, vomiting, diarrhoea), vasovagal reactions, and orthostatic hypotension. There is no specific antidote for plerixafor overdose. If overdose occurs, the patient should be monitored for signs and symptoms of adverse reactions and given appropriate supportive treatment.
| Patient Group | Dose | Route | Special Considerations |
|---|---|---|---|
| Adults (normal renal function) | 20 mg or 0.24 mg/kg/day | Subcutaneous | Weigh patient within 1 week of first dose |
| Adults (CrCl ≤50 ml/min) | 0.16 mg/kg/day | Subcutaneous | Max 27 mg/day; monitor renal function |
| Children (1–17 years) | 0.24 mg/kg/day | Subcutaneous | Weight-based dosing; specialist supervision |
| Elderly | As per adult dosing | Subcutaneous | Adjust based on renal function; cardiac monitoring |
What Are the Side Effects of Plerixafor Seacross?
The most common side effects of Plerixafor Seacross include gastrointestinal symptoms (diarrhoea, nausea, vomiting), injection site reactions, headache, dizziness, and fatigue. Serious but uncommon side effects include allergic reactions (including anaphylaxis) and myocardial infarction in patients with pre-existing cardiac risk factors.
Like all medicines, Plerixafor Seacross can cause side effects, although not everybody gets them. Most side effects observed during clinical trials were mild to moderate in severity and of short duration. It is important to remember that plerixafor is always used together with G-CSF, so some side effects may be attributable to G-CSF, to the underlying disease, or to the apheresis procedure itself rather than to plerixafor specifically.
The side effect profile of plerixafor has been well characterised in pivotal Phase III clinical trials (AMD3100-3101 and AMD3100-3102) involving patients with non-Hodgkin lymphoma and multiple myeloma, as well as in extensive post-marketing surveillance. Because Plerixafor Seacross contains the same active substance at the same strength as the originator product, the expected safety profile is identical. The following frequency classifications follow the standard MedDRA conventions used by the European Medicines Agency.
Very Common (affects more than 1 in 10 people)
- Diarrhoea
- Nausea
- Injection site reactions (redness, irritation, pain, swelling)
- Anaemia / low red blood cell count (particularly in children)
Common (affects up to 1 in 10 people)
- Headache
- Dizziness
- Fatigue and malaise
- Insomnia and sleep disturbances
- Flatulence (gas)
- Constipation
- Dyspepsia (indigestion)
- Vomiting
- Abdominal pain, bloating, or discomfort
- Dry mouth
- Oral hypoaesthesia (numbness around the mouth)
- Hyperhidrosis (excessive sweating)
- Generalised erythema (skin redness)
- Arthralgia (joint pain)
- Musculoskeletal pain and bone pain
Uncommon (affects up to 1 in 100 people)
- Allergic reactions (skin rash, urticaria, periorbital swelling)
- Anaphylactic reactions, including anaphylactic shock
- Abnormal dreams and nightmares
- Myocardial infarction (in patients with cardiac risk factors)
Rare and Post-Marketing Reports
- Severe gastrointestinal events (severe diarrhoea, severe vomiting)
- Splenic enlargement (splenomegaly)
- Splenic rupture (very rare, reported in association with G-CSF)
- Vasovagal reactions and orthostatic hypotension
- Dyspnoea (shortness of breath) and hypoxia
Cardiac Risk
In clinical studies, patients with pre-existing cardiovascular risk factors experienced uncommon cases of myocardial infarction after receiving plerixafor in combination with G-CSF. The causal relationship has not been definitively established, as these patients had significant underlying cardiovascular disease and were also receiving G-CSF, which has its own cardiac effects. Nevertheless, patients with known cardiac risk factors should be carefully evaluated before starting Plerixafor Seacross and monitored throughout treatment. Seek immediate medical attention if you experience chest pain, tightness, or pressure, shortness of breath, pain radiating to the arm, jaw, or back, or sudden onset of nausea and cold sweats.
Leukocytosis (Elevated White Blood Cell Count)
An increase in white blood cell count is an expected pharmacological effect of both G-CSF and plerixafor. Your doctor will perform regular blood tests to monitor your white blood cell count throughout the mobilisation process. In most cases, the leukocytosis is transient and resolves spontaneously after completion of mobilisation. However, if counts become excessively high (>100 × 109/L), the treating team may discontinue plerixafor and proceed with apheresis early to avoid complications from hyperviscosity.
Paraesthesia and Numbness
Tingling sensations (paraesthesia) and numbness are common in patients undergoing cancer treatment and stem cell mobilisation. Approximately one in five patients may experience these symptoms, often around the mouth or in the extremities. Studies suggest that this frequency is not significantly increased by the addition of plerixafor to G-CSF, indicating that paraesthesia is likely related to the underlying disease, prior chemotherapy, or the citrate used during apheresis rather than to plerixafor specifically.
It is important to report suspected side effects after a medicine has been authorised. This enables ongoing monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients can report suspected adverse reactions through their national reporting system, such as the FDA MedWatch programme (US), the MHRA Yellow Card Scheme (UK), or the EMA EudraVigilance system (EU). Reporting of generic products is equally important to detect any batch-specific quality issues.
How Should You Store Plerixafor Seacross?
Plerixafor Seacross should be stored at room temperature with no special storage conditions required. Keep out of the sight and reach of children and do not use after the expiry date. Once the vial has been opened, the solution should be used immediately and any unused portion discarded.
The following storage guidelines apply to Plerixafor Seacross solution for injection:
- Temperature: No special temperature storage conditions are required. Store at room temperature (below 25°C)
- Light protection: No special light protection requirements; the vial itself protects the solution from light
- After opening: The solution should be used immediately once the vial has been opened. Plerixafor Seacross does not contain preservatives, so any unused solution must be discarded
- Expiry date: Do not use Plerixafor Seacross after the expiry date stated on the carton and vial label. The expiry date refers to the last day of that month
- Appearance: Before use, the solution should be visually inspected. It should be clear, colourless to slightly yellow, and free from visible particles. Do not use if the solution is discoloured, cloudy, or contains particles
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist or hospital how to dispose of medicines no longer required. These measures help to protect the environment
- Keep out of reach of children: Store this medicine out of the sight and reach of children at all times
In hospital pharmacy practice, Plerixafor Seacross should be stored in its original carton until use to protect the integrity of the labelling. Stock rotation should follow first-expiry-first-out (FEFO) principles. Because the product is administered in a controlled clinical setting, transport between pharmacy and clinical area does not normally require specialised temperature monitoring.
What Does Plerixafor Seacross Contain?
Each vial of Plerixafor Seacross contains 24 mg of plerixafor in 1.2 ml of solution (concentration: 20 mg/ml). The other ingredients are sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections.
Active Ingredient
The active substance is plerixafor. Each millilitre of solution for injection contains 20 mg of plerixafor. Each single-use glass vial contains 1.2 ml of solution, providing a total of 24 mg of plerixafor per vial. Plerixafor is a bicyclam compound (chemical name: 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]) with a molecular weight of 502.78 g/mol. The compound is a symmetric macrocyclic molecule originally developed as an anti-HIV agent before its effect on CXCR4 and stem cell mobilisation was identified.
Excipients (Inactive Ingredients)
- Sodium chloride: Used to make the solution isotonic (compatible with body fluids and tissues)
- Hydrochloric acid (concentrated): Used for pH adjustment to physiological range
- Sodium hydroxide: Used for pH adjustment to physiological range
- Water for injections: Solvent
The formulation does not contain preservatives, animal-derived components, gluten, lactose, or sugars. This simple composition minimises the risk of hypersensitivity reactions to excipients and makes the product suitable for patients with a wide range of dietary restrictions or allergies.
Appearance and Packaging
Plerixafor Seacross is supplied as a clear, colourless to slightly yellow solution for injection in a Type I glass vial with a latex-free rubber stopper sealed with an aluminium flip-off cap. Each carton contains one single-use vial containing 1.2 ml of solution. The vial is designed for single use only; any unused portion must be discarded after the dose has been withdrawn. The outer carton carries a tamper-evident seal and the regulatory batch information required for traceability.
Manufacturer and Marketing Authorisation
Plerixafor Seacross is manufactured under Good Manufacturing Practice (GMP) conditions and has been approved by the relevant regulatory authority as a generic equivalent of the originator plerixafor product. The product must meet the same pharmaceutical quality standards – including identity, purity, sterility, and stability – as the reference product. The marketing authorisation holder is Seacross Pharmaceuticals Ltd. Always refer to the product label and the locally approved Summary of Product Characteristics (SmPC) for the most current information on manufacturer, batch, and expiry details.
Frequently Asked Questions About Plerixafor Seacross
Plerixafor Seacross is used in combination with G-CSF to mobilise haematopoietic (blood-forming) stem cells from the bone marrow into the peripheral bloodstream. These stem cells are then collected through a process called apheresis and stored for later use in autologous stem cell transplantation. It is indicated for adults with lymphoma or multiple myeloma who are poor mobilisers, and for children aged 1 to under 18 years with lymphoma or solid tumours. The active substance plerixafor is a CXCR4 antagonist first approved by the EMA in 2009.
Plerixafor Seacross is a generic version of Mozobil. Both products contain the same active ingredient (plerixafor) at the same concentration (20 mg/ml) and have the same dosage form (solution for injection). Generic medicines must demonstrate bioequivalence to the originator, meaning they deliver the same amount of active substance to the body in the same way, and produce the same therapeutic effect. The main differences are in manufacturer, packaging, and price – generics are typically more affordable, expanding access to treatment for healthcare systems and patients.
Plerixafor Seacross works by blocking the CXCR4 receptor on haematopoietic stem cells. Under normal conditions, a protein called SDF-1α (CXCL12) binds to this receptor and anchors stem cells within the bone marrow microenvironment. By blocking this interaction, plerixafor allows the stem cells to be released into the bloodstream, where they can be collected by apheresis. When used with G-CSF, which has already expanded the stem cell pool over several days, plerixafor provides an additional rapid surge of stem cells into the blood, increasing the likelihood of a successful collection.
Plerixafor and G-CSF work through different but complementary mechanisms. G-CSF stimulates the bone marrow to produce more stem cells and gradually releases them over several days. Plerixafor then provides a rapid additional release by blocking the receptor that holds stem cells in the bone marrow. Together, they achieve significantly higher stem cell yields than either agent alone, which is critical for ensuring that enough cells are collected for a successful transplant. Using plerixafor alone would release existing stem cells from the marrow, but without G-CSF to expand the pool first, the yield would be insufficient for most patients.
Plerixafor Seacross is typically administered by healthcare professionals in a hospital or clinical setting, as it is part of a complex stem cell mobilisation and collection programme that requires close medical supervision, including apheresis procedures and daily blood monitoring. In some healthcare systems, selected patients may be trained to self-administer the subcutaneous injection at home the evening before apheresis under the guidance of their transplant team, particularly if they are experienced with subcutaneous injections and live far from the treatment centre. This decision is made on an individual basis by the treating physician.
If insufficient stem cells are collected despite treatment with G-CSF and Plerixafor Seacross, the collection attempt may be extended for additional days (up to a maximum of 7 days of plerixafor). If the target CD34+ cell dose still cannot be achieved, the transplant team will discuss alternative strategies, which may include additional mobilisation attempts at a later date after a "rest period", chemo-mobilisation using high-dose cyclophosphamide followed by G-CSF and plerixafor, bone marrow harvest under general anaesthesia, or reassessment of the overall treatment plan. The decision is individualised based on the patient's clinical situation.
Plerixafor Seacross can be used in patients with kidney problems, but the dose must be adjusted. Since plerixafor is primarily excreted by the kidneys, patients with moderate to severe renal impairment (creatinine clearance ≤50 ml/min) should receive a reduced dose of 0.16 mg/kg/day instead of the standard 0.24 mg/kg/day, with a maximum of 27 mg per day. There is limited experience in patients with very severe kidney disease or those on dialysis, so careful evaluation by the transplant team is essential, and additional monitoring may be required in these cases.
References
- European Medicines Agency (EMA). Plerixafor – European Public Assessment Report (EPAR) and Summary of Product Characteristics. Last updated 2024.
- US Food and Drug Administration (FDA). Plerixafor injection – Prescribing Information. Current label, 2023.
- DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–5726.
- DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767–4773.
- Duarte RF, Chabannon C, Bernasconi P, et al. Plerixafor for stem cell mobilisation: the European perspective. Bone Marrow Transplant. 2018;53(5):543–551.
- National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance TA465: Plerixafor for stem cell mobilisation in lymphoma and multiple myeloma. 2017.
- Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.
- Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31–40.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- European Society for Blood and Marrow Transplantation (EBMT). EBMT Handbook: Haematopoietic Stem Cell Transplantation and Cellular Therapies. 8th Edition, 2024.
- British National Formulary (BNF). Plerixafor monograph. Current online edition.
- Modak RV, Mondal P, Nandi S, et al. Generic plerixafor: evidence of interchangeability in haematopoietic stem cell mobilisation. Bone Marrow Transplant. 2023;58(10):1123–1131.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in haematology, oncology, clinical pharmacology, and stem cell transplantation.
iMedic Medical Editorial Team – specialists in haematology and clinical pharmacology with experience in stem cell transplantation and supportive care.
iMedic Medical Review Board – independent panel of medical experts who verify accuracy, completeness, and adherence to international guidelines (EBMT, ASTCT, NICE, EMA, FDA).
This article follows the GRADE evidence framework and is based on systematic reviews, randomised controlled trials, and international clinical guidelines. All content is independently produced with no commercial funding or pharmaceutical industry sponsorship. Last reviewed: .